RxDoctor Payments Data

Harinder Singh, MD

Nephrology · Allentown, PANPI 1710928049

Payments from drug & device makers

$988in general payments, 2019–2025

Across 25 payments — averaging $39.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$185
  • Lilly USA, LLC$146
  • E.r. Squibb & Sons, L.L.C.$125
  • Bayer$124
  • Boehringer Ingelheim$85
  • Fresenius USA Marketing, Inc.$65
  • plus $257 from 7 others

What the payments were for

  • Food & beverage$988100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$988 in reported general payments places this provider in the 55th percentile of 586 nephrology providers in Pennsylvania.

See all nephrology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$140,001
Medicare patients
351
Services billed
2,421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin81$62,872
FarxigaDapagliflozin Propanediol56$28,583
DapagliflozinDapagliflozin Propanediol13$6,870
Sevelamer Carbonate31$2,230
Amlodipine Besylate268$1,869
Calcitriol137$1,818
Valsartan72$1,467
Torsemide117$1,412
Potassium Citrate ErPotassium Citrate11$1,265
Doxazosin Mesylate49$1,110
Metoprolol Succinate49$1,015
Potassium Chloride25$830
Olmesartan Medoxomil78$820
Hydrochlorothiazide102$756
Lisinopril80$666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$85$62,87281 claims
AstraZenecaFarxiga$185$28,58356 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 586 nephrology providers in Pennsylvania.

Other nephrology in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →